N
Naoto T. Ueno
Researcher at University of Texas MD Anderson Cancer Center
Publications - 390
Citations - 13778
Naoto T. Ueno is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Inflammatory breast cancer. The author has an hindex of 59, co-authored 389 publications receiving 11623 citations. Previous affiliations of Naoto T. Ueno include University of Texas Health Science Center at Houston & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial
HS Rugo,William Jacot,Eiji Tokunaga,J. Sohn,Fernanda Camila Cardoso,B. Xu,Maria Vidal Losada,María José Gil,Naoto T. Ueno,Aleix Prat,Haim G. Moore,U. Hasler-Strub,D. Cameron,Henrik Lindman,Klara Mezei,Ramakrishnan Rajagopalan,Cecilia Orbegoso,Fu-Chih Cheng,Ansuya Puri,Shanu Modi +19 more
TL;DR: In this article , the authors compared T-DXd vs TPC in pts with HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization-negative) mBC, with manageable safety.
Journal ArticleDOI
Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy
Colleen M. Costelloe,Patrick P. Lin,Hubert H. Chuang,Behrang Amini,Sudpreeda Chainitikun,Tse Kuan Yu,Naoto T. Ueno,William A. Murphy,John E. Madewell +8 more
TL;DR: The roles of CT, skeletal scintigraphy, SPECT/CT, MRI, PET/CT and PET/MRI will be reviewed and therapeutic response criteria specifically designed to evaluate bone metastases can guide image interpretation.
Book ChapterDOI
Trials and Tribulations in Developing Clinical Trials of Gene Therapy
TL;DR: This chapter highlights some of the issues and difficulties the team encountered in designing clinical trials of E1A gene therapy for breast or ovarian cancer.
Journal ArticleDOI
Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''.
TL;DR: Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy’’
Book ChapterDOI
Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study
Peter B. Vermeulen,Gert Van den Eynden,Pascal Finetti,Daniel Birnbaum,Naoto T. Ueno,Patrice Viens,François Bertucci,Luc Y. Dirix,Steven Van Laere +8 more
TL;DR: Comparative analysis of all the data suggests that angiogenesis in IBC is not VEGFA-driven but is merely a consequence of a disturbed balance between proangiogenic and antiangiogenesis factors, possibly involving PGF, TSP1 (THBS1) and the miR-221/-222-family.